Carematrix launches blinded remote monitoring tech for clinical trials
US-based Carematrix has launched a blinded blood pressure monitor and scale designed to remotely monitor patients’ vitals in blinded clinical…
All articles by Phalguni Deswal
Phalguni Deswal
@Phalguni_GD
Phalguni Deswal is reporter in the healthcare and pharmaceutical sector. With a background in medicine, Phalguni has experience working in the Indian healthcare sector. Phalguni is interested in metabolic drug therapies, digital health technologies, and drug development.
-
-
Medtronic teases positive data adaptive deep brain stimulation trial
Medtronic has published preliminary data from a study of its adaptive deep brain stimulation (aDBS) device, Percept PC neurostimulator, in…
-
FDA releases draft guidance on oncology multiregional clinical trials
The US Food and Drug Administration (FDA) has released a new draft guidance on multiregional clinical trials (MRCTs) in oncology…
-
ESMO 2024: Natera showcases chemotherapy prediction benefit of cDNA test
Natera has released new data from the GALAXY arm of its ongoing CIRCULATE-Japan trial showing the efficacy of its molecular…
-
Alio starts trial to expand label for remote monitoring device
US-based Alio plans to increase the use case for its wearable remote monitoring SmartPatch technology to monitor health metrics in…
-
EASD 2024: Innovent shows off mazdutide’s efficacy in diabetes and obesity
Innovent Biologics has released more data from two Phase III trials evaluating mazdutide in adults with type 2 diabetes and…
-
EASD 2024: Novo Nordisk’s Saxenda shows weight loss in children
Novo Nordisk showcased the efficacy of its obesity therapy, Saxenda (liraglutide), in children under 12 years of age with positive…
-
EASD 2024: Eli Lilly releases Phase III data for once-weekly insulin in diabetes
Eli Lilly has released detailed results from the Phase III QWINT-2 and QWINT-5 trial showing that its once-weekly insulin efsitora…
-
EASD 2024: PolTREG’s T cell therapy shows long-term remission in type 1 diabetes
PolTREG has presented positive long-term data for its cell therapy, PTG-007, showing that the therapy induced clinical remission for type…
-
Tempo doses first patient with tissue scaffolds in cancer surgery trial
Tempo Therapeutics has started the first in-human trial for its tissue regeneration product, TT101, in patients who have undergone surgical…